This is a single-arm, non-randomized study of ARQ 501 in combination with gemcitabine in adult patients with treatment-naïve, unresectable, metastatic pancreatic adenocarcinoma. The study objectives are:~Primary Objective:~Assess the overall response rate (ORR) of patients treated with ARQ 501 in combination with gemcitabine.~Secondary Objectives:~Determine time to tumor progression (TTP) of patients treated with ARQ 501 in combination with gemcitabine~Further characterize the safety of ARQ 501 in combination with gemcitabine
The study will document the safety and efficacy of the combination of ARQ 501 and gemcitabine in patients with treatment-naïve, unresectable, metastatic pancreatic adenocarcinoma.